Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FK949E (Quetiapine) for Bipolar Depression
NCT01725308Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Feb 2012
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of quetiapine (extended-release tablet, brand name: Bipresso) in bipolar disorder (BD) (3 arms), sponsored by Astellas Pharma. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 8 weeks. Started Feb 2012; status: completed.
02
Drugs
quetiapine (extended-release tablet, brand name: Bipresso)
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT01725308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01725308.